 NEW HAVEN, Conn., Nov. 15, 2021 PRNewswire -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will be presenting at the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases taking place from November 16-18, 2021 in Boston, MA. 